Nebenwirkungen · Sitagliptin / Metformin hydrochloride Sun
Sitagliptin/Metformin hydrochloride SUN 50 mg/850 mg film-coated tablets Sitagliptin/Metformin hydrochloride SUN 50 mg/1 000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11
HOS-149452 · Präparat HOS-100052
In the intention-to-treat population, among patients who were using insulin and/or a sulfonylurea at baseline, the incidence of severe hypoglycaemia was 2.7 % in sitagliptin-treated patients and 2.5 % in placebo-treated patients; among patients who were not using insulin and/or a sulfonylurea at baseline, the incidence of severe hypoglycaemia was 1.0 % in sitagliptin-treated patients and 0.7 % in placebo- treated patients. The incidence of adjudication-confirmed pancreatitis events was 0.3 % in sitagliptin- treated patients and 0.2 % in placebo-treated patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-06T12:11:00Z · SHA-256 fd7e3c6c3895b7e664b95bd3e0199493082d8eb279c262d7cecdfbfc68d7c194 · Passage 710233076aea573cde5f3df1a1ec1d43a8ee2c7f10aeb37e7fc519c520ff01ac · Zeichen 6609–7177 im Abschnitt